4 mg Fesoterodine ER tablet from Zwickau + 4 mg fesoterodine ER tablet from Freiburg + 8 mg fesoterodine ER tablet from Zwickau + 8 mg fesoterodine ER tablet from Freiburg
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neurogenic Detrusor Overactivity
Conditions
Neurogenic Detrusor Overactivity
Trial Timeline
Nov 12, 2019 → Nov 12, 2020
NCT ID
NCT04478357About 4 mg Fesoterodine ER tablet from Zwickau + 4 mg fesoterodine ER tablet from Freiburg + 8 mg fesoterodine ER tablet from Zwickau + 8 mg fesoterodine ER tablet from Freiburg
4 mg Fesoterodine ER tablet from Zwickau + 4 mg fesoterodine ER tablet from Freiburg + 8 mg fesoterodine ER tablet from Zwickau + 8 mg fesoterodine ER tablet from Freiburg is a phase 1 stage product being developed by Pfizer for Neurogenic Detrusor Overactivity. The current trial status is completed. This product is registered under clinical trial identifier NCT04478357. Target conditions include Neurogenic Detrusor Overactivity.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04478357 | Phase 1 | Completed |
Competing Products
20 competing products in Neurogenic Detrusor Overactivity